Why is Bliss GVS Pharma falling/rising?

As of 23-Sep, Bliss GVS Pharma Ltd is experiencing a slight decline in its stock price, currently at 151.15, down by 0.25 or 0.17%. The stock's performance today is in line with its sector, although it is trading lower than its 5-day, 20-day, and 50-day moving averages, while remaining higher than the 100-day and 200-day moving averages. The stock has seen a notable increase in investor participation, with delivery volume rising by 18.82% against the 5-day average. Over the past year, Bliss GVS Pharma has generated a return of 11.18%, but its profits have decreased by 3.6%, indicating a mixed performance. The company maintains a low debt-to-equity ratio and a fair valuation, trading at a premium compared to its peers, which suggests a cautious outlook among investors.
In the broader market context, the stock's short-term performance over the past week shows a decline of 0.20%, which is better than the benchmark Sensex's drop of 0.34%. However, over the past month, Bliss GVS Pharma has underperformed significantly, with a decrease of 6.38% compared to the Sensex's increase of 0.98%. Despite the stock's consistent returns over the last three years, outperforming the BSE500 annually, the recent profit decline may be contributing to investor hesitance, leading to the current downward movement in price.